Xeris Biopharma (NASDAQ:XERS) Earns "Neutral" Rating from Piper Sandler

Key Points

• Piper Sandler reaffirmed its Neutral rating on Xeris Biopharma but raised its price target from $8 to $12, implying 13.97% downside from the prior close.
• Analyst views overall remain favorable: MarketBeat reports a Moderate Buy consensus and a $15.60 average price target, with HC Wainwright raising its target to $18 and maintaining a Buy rating.
• Xeris beat quarterly estimates, posting EPS of $0.06 versus $0.03 expected and revenue of $107.23 million versus $101.68 million expected.

Xeris Biopharma (NASDAQ:XERS - Get Free Report)'s stock had its "neutral" rating reissued by equities research analysts at Piper Sandler in a report issued on Friday, Benzinga reports. They currently have a $12.00 price target on the stock, up from their previous price target of $8.00. Piper Sandler's price objective suggests a potential downside of 13.97% from the stock's previous close.

A number of other brokerages have also weighed in on XERS. HC Wainwright increased their target price on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday. Barclays boosted their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Leerink Partners upped their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday, September 10th. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $13.95 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The stock has a fifty day simple moving average of $9.49 and a two-hundred day simple moving average of $7.58. Xeris Biopharma has a 1-year low of $5.25 and a 1-year high of $13.74. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -127.09 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Analysts anticipate that Xeris Biopharma will post 0.07 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 15,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $153,450.00. Following the sale, the insider directly owned 1,584,208 shares in the company, valued at $16,206,447.84. This trade represents a 0.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 148,332 shares of company stock worth $1,409,221. 4.35% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently bought and sold shares of the company. Knights of Columbus Asset Advisors LLC bought a new stake in Xeris Biopharma during the third quarter valued at approximately $1,275,000. StoneX Group Inc. bought a new position in shares of Xeris Biopharma in the 3rd quarter worth $142,000. Pictet Asset Management Holding SA increased its holdings in shares of Xeris Biopharma by 13.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company's stock worth $326,000 after buying an additional 4,108 shares during the last quarter. AlphaCentric Advisors LLC raised its position in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company's stock valued at $464,000 after buying an additional 1,940 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of Xeris Biopharma by 3.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 213,337 shares of the company's stock valued at $2,040,000 after buying an additional 7,482 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results topped expectations: Xeris reported earnings of $0.06 per share versus consensus of $0.03, while revenue of $107.23 million exceeded the $101.68 million estimate. The results helped drive the positive stock response. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Stronger Recorlev sales outlook: CEO John Shannon reportedly sees Recorlev approaching $1 billion in annual sales three to four years earlier than previously expected. Xeris also updated its FY 2030 earnings guidance, though the supplied report does not provide the revised figures. Xeris CEO Sees Recorlev Nearing $1B in Annual Sales Earlier Than Expected
• Positive Sentiment: Analyst raised target: HC Wainwright lifted its price target from $10 to $18 and maintained a Buy rating, signaling confidence in further upside. HC Wainwright recommendations
• Negative Sentiment: Insider sales: Several executives sold shares at $10.23, including Steven Pieper, Kevin McCulloch and Beth Hecht. The transactions were made under pre-arranged 10b5-1 plans, and each retained substantial holdings, which may temper the negative signal. Xeris Biopharma Insider Trading

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.